comparemela.com

Latest Breaking News On - Martin schmieg - Page 1 : comparemela.com

BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K -April 02, 2024 at 04:09 pm EDT

NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS In accordance with National Instrument 51-102 Part 4, subsection 4.3, if.

United kingdomUnited statesBritish columbiaMartin schmiegWilliam williamsNational instrumentCompany to briacellServices to briaproToronto stock exchangeTransition services agreementInternational financial reporting standardsBriapro therapeutics corpBriacell therapeutics corpInternational financial reporting interpretations committeeInternational accounting standardsInternational accounting standards board

BriaCell Therapeutics : BRIAPRO THERAPEUTIC CORP CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2023 - Form 8-K -December 14, 2023 at 05:07 pm EST

BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2023 .

British columbiaUnited statesUnited kingdomWilliam williamsMartin schmiegInternational financial reporting interpretations committeeBriapro therapeutics corpToronto stock exchangeBriacell therapeutics corpTransition services agreementInternational accounting standardsServices to briaproCompany to briacellInternational accounting standards boardInternational financial reporting standardsUnited states dollars

BriaCell Therapeutics : BRIAPRO THERAPEUTIC CORP FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2023 - Form 8-K -October 25, 2023 at 05:29 pm EDT

BRIAPRO THERAPEUTIC CORP. FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2023 .

British columbiaUnited kingdomUnited statesWilliam williamsMartin schmiegBriapro therapeutics corpInternational financial reporting standardsBriacell therapeutics corpInternational accounting standards boardServices to briaproInterpretations committeeTransition services agreementToronto stock exchangeCompany to briacellUnited states dollarsFinancial position

BriaCell Therapeutics Corp Announces Results of Shareholder Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company for the years ended July 31, 2019 and July 31, 2020 held on May 18, 2021 . A total of 1,685,180 common shares of the Company were voted, representing 22.36% of the Company’s … BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the ” Shareholders “) for the years ended July 31, 2019 and July 31, 2020 held on May 18, 2021 (the ” Meeting “). A total of 1,685,180 common shares of the Company (the ” Common Sh

Martin schmiegRichard bermanRebecca taubVaughnc embro pantalonyCharles wisemanWilliamv williamsJules abrahamJamieson bondarenkoCompany the shareholdersCompany contactCompany the commonRatification of the companyBriacell therapeutics corpRenewal of the companyVenture exchangeRegulation services provider

vimarsana © 2020. All Rights Reserved.